Who is a good candidate for this therapy?

Ideal candidates are adults with relapsed or refractory multiple myeloma who have tried at least three prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients must have adequate organ function and no active infections. Contraindications include active central nervous system involvement, significant comorbidities like severe heart failure, or prior allogeneic stem cell transplant with active graft-versus-host disease. A thorough evaluation by a hematologist-oncologist determines eligibility.